| abstract |
PROBLEM TO BE SOLVED: To provide GDF-15 as a safety biomarker for determining the toxicological action of an Mdm2 inhibitor, particularly the hematological toxicity of an Mdm2 inhibitor. In particular, it relates to the use of GDF-15 as a safety biomarker to determine the likelihood of developing thrombocytopenia in a subject in response to administration of an Mdm2 inhibitor. An ex vivo method for determining the likelihood of developing thrombocytopenia in a subject in response to administration of an Mdm2 inhibitor, a method of using an Mdm2 inhibitor in the treatment of cancer in a subject, cancer. A kit for use in predicting the likelihood that a patient with thrombocytopenia will develop thrombocytopenia in response to treatment with a dose of Mdm2 inhibitor, for use in treating a patient with cancer With respect to the kit and related disclosure embodiments. [Selection diagram] None |